A Study in Patients With Trichotillomania

NCT03797521 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Trichotillomania

Interventions

DRUG: SXC-2023
DRUG: Placebo

Sponsor

Promentis Pharmaceuticals, Inc.